Drug Trial Radar · NCT07808151
Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon Cancer
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Nov 30, 2026
Primary completion
Sep 30, 2029
Study completion Sep 30, 2029
Sponsor
- Lead sponsor
- Solstice Oncology, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 8, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if giving two medicines together, porustobart and pembrolizumab, before surgery can treat a common type of colon cancer called microsatellite stable (MSS) colon cancer in adults. This type of cancer can be removed with surgery and has not spread to other parts of the body. Both medicines work by helping the immune system fight cancer. The main questions this study wants to answer: How well do the medicines destroy the cancer before surgery? What side effects do participants have when taking the medicines? Researchers will compare two groups to see which treatment schedule works better and is safer. Both groups get pembrolizumab. One group gets one dose of porustobart (Day 1 only), and the other group gets two doses (Day 1 and Day 22). Participants will: Complete certain tests and procedures to make sure they are eligible Get the medicines through a vein on Day 1 and Day 22 then have surgery 6-9 weeks after starting treatment Return for checkups and tests every 6 months for up to 3 years after surgery
Conditions
- Colon Cancer
Interventions
PembrolizumabDrug
Administered to: Dose Schedule 1 - Porustobart + Pembrolizumab, Dose Schedule 2 - Porustobart + Pembrolizumab
PorustobartDrug
Administered to: Dose Schedule 1 - Porustobart + Pembrolizumab, Dose Schedule 2 - Porustobart + Pembrolizumab
Primary outcomes
What the sponsor says the trial is designed to measure.
- Major Pathologic Response (MPR) rate by Blinded Independent Pathologic Review (BIPR)Time frame: Assessed from surgical resection specimen (surgery occurs Day 42-Day 63, i.e., approximately Week 6-Week 9 after first dose)
Locations
30 sites in 6 countries. Site status is shown where the registry gives one.
Investigator Site
Los Angeles, California · Recruiting
Investigator Site
Tampa, Florida · Not yet recruiting
Investigator Site
Chicago, Illinois · Not yet recruiting
Investigator Site
Baltimore, Maryland · Recruiting
Investigator Site
Boston, Massachusetts · Not yet recruiting
Investigator Site
New York, New York · Not yet recruiting
Investigator Site
New York, New York · Not yet recruiting
Investigator Site
New York, New York · Not yet recruiting
Investigator Site
Cleveland, Ohio · Recruiting
Investigator Site
Nashville, Tennessee · Not yet recruiting
Investigator Site
Seattle, Washington · Recruiting
Investigator Site
Anderlecht, Belgium · Not yet recruiting
Investigator Site
Bonheiden, Belgium · Not yet recruiting
Investigator Site
Ghent, Belgium · Not yet recruiting
Investigator Site
Leuven, Belgium · Not yet recruiting
Investigator Site
Liège, Belgium · Not yet recruiting
Investigator Site
Ostend, Belgium · Not yet recruiting
Investigator Site
Woluwe-Saint-Lambert, Belgium · Not yet recruiting
Investigator Site
Milan, Italy · Not yet recruiting
Investigator Site
Naples, Italy · Not yet recruiting
Investigator Site
Pisa, Italy · Not yet recruiting
Investigator Site
Amsterdam, Netherlands · Not yet recruiting
Investigator Site
Barcelona, Spain · Not yet recruiting
Investigator Site
L'Hospitalet de Llobregat, Spain · Not yet recruiting
Investigator Site
Madrid, Spain · Not yet recruiting
Investigator Site
Aberdeen, United Kingdom · Not yet recruiting
Investigator Site
Cardiff, United Kingdom · Not yet recruiting
Investigator Site
Glasgow, United Kingdom · Not yet recruiting
Investigator Site
Leeds, United Kingdom · Not yet recruiting
Investigator Site
London, United Kingdom · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.